Press coverage about Versartis (NASDAQ:VSAR) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Versartis earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.3254167117703 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Versartis (NASDAQ:VSAR) opened at $2.03 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.52 and a current ratio of 1.52. Versartis has a 12-month low of $1.60 and a 12-month high of $24.00.
Versartis (NASDAQ:VSAR) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.78). During the same period last year, the business earned ($0.92) earnings per share. research analysts anticipate that Versartis will post -4.14 EPS for the current fiscal year.
In other news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the firm’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $3.29, for a total value of $7,007,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 2,132,769 shares of company stock valued at $7,014,761. 10.90% of the stock is currently owned by insiders.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
What are top analysts saying about Versartis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Versartis Inc. and related companies.